Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease

NeuroMolecular Medicine

Volumn 15, Issue 2, 2013, Pages 295-309

  Villar Menéndez, Izaskun ^a   Blanch, Marta ^a   Tyebji, Shiraz ^b,c,d   Pereira Veiga, Thais ^a   Albasanz, José Luis ^e   Martín, Mairena ^e   Ferrer, Isidre ^a,b,d   Pérez Navarro, Esther ^b,c,d   Barrachina, Marta ^a,d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

5 Hydroxymethylcytosine; 5 Methylcytosine; Adenosine A2A receptor; ADORA2A; Huntington's disease

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; ADENOSINE A2A RECEPTOR;

5' UNTRANSLATED REGION; ADENOSINE A2A RECEPTOR GENE; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DNA METHYLATION; DOWN REGULATION; EXON; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUTAMEN;

5' UNTRANSLATED REGIONS; 5-METHYLCYTOSINE; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CORPUS STRIATUM; CYTOSINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NERVE TISSUE PROTEINS; PUTAMEN; RECEPTOR, ADENOSINE A2A;

MUS;

EID: 84877744385     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-013-8219-0     Document Type: Article

References (86)

1. Assaife-Lopes, N.; Sousa, V. C.; Pereira, D. B.; Ribeiro, J. A.; Chao, M. V.; & Sebastião, A. M. (2010). Activation of adenosine A2A receptors induces TrkB translocation and increases BDNF-mediated phospho-TrkB localization in lipid rafts: Implications for neuromodulation. The Journal of Neuroscience, 30(25), 8468-8480.
2. Bañez-Coronel, M.; Porta, S.; Kagerbauer, B.; Mateu-Huertas, E.; Pantano, L.; Ferrer, I.; et al. (2012). A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genetics, 8(2), e1002481.
3. Barrachina, M.; & Ferrer, I. (2009). DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. Journal of Neuropathology and Experimental Neurology, 68(8), 880-891.
4. Bauer, A.; Zilles, K.; Matusch, A.; Holzmann, C.; Riess, O.; & von Hörsten, S. (2005). Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation. Journal of Neurochemistry, 94(3), 639-650.
5. Blum, D.; Galas, M. C.; Pintor, A.; Brouillet, E.; Ledent, C.; Muller, C. E.; et al. (2003). A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: Implications for the neuroprotective potential of A2A antagonists. The Journal of Neuroscience, 23(12), 5361-5369.
6. Brohede, J.; Rinde, M.; Winblad, B.; & Graff, C. (2010). A DNA methylation study of the amyloid precursor protein gene in several brain regions from patients with familial Alzheimer disease. Journal of Neurogenetics, 24(4), 179-181.
7. Buira, S. P.; Albasanz, J. L.; Dentesano, G.; Moreno, J.; Martín, M.; Ferrer, I.; et al. (2010a). DNA methylation regulates adenosine A(2A) receptor cell surface expression levels. Journal of Neurochemistry, 112(5), 1273-1285.
8. Buira, S. P.; Dentesano, G.; Albasanz, J. L.; Moreno, J.; Martín, M.; Ferrer, I.; et al. (2010b). DNA methylation and Yin Yang-1 repress adenosine A2A receptor levels in human brain. Journal of Neurochemistry, 115(1), 283-295.
9. Calon, F.; Dridi, M.; Hornykiewicz, O.; Bédard, P. J.; Rajput, A. H.; & Di Paolo, T. (2004). Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain, 127(Pt 5), 1075-1084.
10. Cha, J. H.; Frey, A. S.; Alsdorf, S. A.; Kerner, J. A.; Kosinski, C. M.; Mangiarini, L.; et al. (1999). Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Science, 354(1386), 981-989.
11. Chen-Plotkin, A. S.; Sadri-Vakili, G.; Yohrling, G. J.; Braveman, M. W.; Benn, C. L.; Glajch, K. E.; et al. (2006). Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiology of Disease, 22(2), 233-241.
12. Chiang, M. C.; Chen, H. M.; Lai, H. L.; Chen, H. W.; Chou, S. Y.; Chen, C. M.; et al. (2009). The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. Human Molecular Genetics, 18(16), 2929-2942.
13. Chiang, M. C.; Lee, Y. C.; Huang, C. L.; & Chern, Y. (2005). cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. The Journal of Biological Chemistry, 280(14), 14331-14340.
14. Choi, Y. J.; Kim, S. I.; Lee, J. W.; Kwon, Y. S.; Lee, H. J.; Kim, S. S.; et al. (2012). Suppression of aggregate formation of mutant huntingtin potentiates CREB-binding protein sequestration and apoptotic cell death. Molecular and Cellular Neurosciences, 49(2), 127-137.
15. Cong, S. Y.; Pepers, B. A.; Evert, B. O.; Rubinsztein, D. C.; Roos, R. A.; van Ommen, G. J.; et al. (2005). Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Molecular and Cellular Neurosciences, 30(4), 560-571.
16. de Boni, L.; Tierling, S.; Roeber, S.; Walter, J.; Giese, A.; & Kretzschmar, H. A. (2011). Next-generation sequencing reveals regional differences of the α-synuclein methylation state independent of Lewy body disease. NeuroMolecular Medicine, 13(4), 310-320.
17. Deckert, J.; Brenner, M.; Durany, N.; Zöchling, R.; Paulus, W.; Ransmayr, G.; et al. (2003). Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. NeuroReport, 14(3), 313-316.
18. Dhaenens, C. M.; Burnouf, S.; Simonin, C.; Van Brussel, E.; Duhamel, A.; Defebvre, L.; et al. (2009). A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiology of Disease, 35(3), 474-476.
19. Feng, J.; Zhou, Y.; Campbell, S. L.; Le, T.; Li, E.; Sweatt, J. D.; et al. (2010). Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nature Neuroscience, 13(4), 423-430.
20. Ferrer, I.; Goutan, E.; Marín, C.; Rey, M. J.; & Ribalta, T. (2000). Brain-derived neurotrophic factor in Huntington disease. Brain Research, 866(1-2), 257-261.
21. Ferrer, I.; Martinez, A.; Boluda, S.; Parchi, P.; & Barrachina, M. (2008). Brain banks: Benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell and Tissue Banking, 9(3), 181-194.
22. Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; & Linden, J. (2001). International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacological Reviews, 53(4), 527-552.
23. Gianfriddo, M.; Melani, A.; Turchi, D.; Giovannini, M. G.; & Pedata, F. (2004). Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiology of Disease, 17(1), 77-88.
24. Ginés, S.; Bosch, M.; Marco, S.; Gavaldà, N.; Díaz-Hernández, M.; Lucas, J. J.; et al. (2006). Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. The European Journal of Neuroscience, 23(3), 649-658.
25. Giralt, A.; Saavedra, A.; Carreton, O.; Xifro, X.; Alberch, J.; & Perez-Navarro, E. (2011). Increased PKA signaling disrupts recognition memory and spatial memory: Role in Huntington's disease. Human Molecular Genetics, 20(21), 4232-4247.
26. Glass, M.; Dragunow, M.; & Faull, R. L. (2000). The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience, 97(3), 505-519.
27. Globisch, D.; Münzel, M.; Müller, M.; Michalakis, S.; Wagner, M.; Koch, S.; et al. (2010). Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS ONE, 5(12), e15367.
28. Guo, J. U.; Ma, D. K.; Mo, H.; Ball, M. P.; Jang, M. H.; Bonaguidi, M. A.; et al. (2011a). Neuronal activity modifies the DNA methylation landscape in the adult brain. Nature Neuroscience, 14(10), 1345-1351.
29. Guo, J. U.; Su, Y.; Zhong, C.; Ming, G. L.; & Song, H. (2011b). Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell, 145(3), 423-434.
30. Hodges, A.; Strand, A. D.; Aragaki, A. K.; Kuhn, A.; Sengstag, T.; Hughes, G.; et al. (2006). Regional and cellular gene expression changes in human Huntington's disease brain. Human Molecular Genetics, 15(6), 965-977.
31. Huang, N. K.; Lin, J. H.; Lin, J. T.; Lin, C. I.; Liu, E. M.; Lin, C. J.; et al. (2011). A new drug design targeting the adenosinergic system for Huntington's disease. PLoS ONE, 6(6), e20934.
32. Huang, H. S.; Matevossian, A.; Jiang, Y.; & Akbarian, S. (2006). Chromatin immunoprecipitation in postmortem brain. Journal of Neuroscience Methods, 156(1-2), 284-292.
33. Ishiwata, K.; Ogi, N.; Hayakawa, N.; Oda, K.; Nagaoka, T.; Toyama, H.; et al. (2002). Adenosine A2A receptor imaging with [11C]KF18446 PET in the rat brain after quinolinic acid lesion: comparison with the dopamine receptor imaging. Annals of Nuclear Medicine, 16(7), 467-475.
34. Jin, S. G.; Kadam, S.; & Pfeifer, G. P. (2010). Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Research, 38(11), e125.
35. Jin, S. G.; Wu, X.; Li, A. X.; & Pfeifer, G. P. (2011). Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nucleic Acids Research, 39(12), 5015-5024.
36. Jones, P. A. (2012). Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nature Reviews Genetics, 13(7), 484-492.
37. Jowaed, A.; Schmitt, I.; Kaut, O.; & Wüllner, U. (2010). Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. The Journal of Neuroscience, 30(18), 6355-6359.
38. Khare, T.; Pai, S.; Koncevicius, K.; Pal, M.; Kriukiene, E.; Liutkeviciute, Z.; et al. (2012). 5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. Nature Structural & Molecular Biology, 19(10), 1037-1043.
39. Kriaucionis, S.; & Heintz, N. (2009). The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science, 324(5929), 929-930.
40. Kuhn, A.; Goldstein, D. R.; Hodges, A.; Strand, A. D.; Sengstag, T.; Kooperberg, C.; et al. (2007). Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics, 16(15), 1845-1861.
41. Li, S. H.; Cheng, A. L.; Zhou, H.; Lam, S.; Rao, M.; Li, H.; et al. (2002). Interaction of Huntington disease protein with transcriptional activator Sp1. Molecular and Cellular Biology, 22(5), 1277-1287.
42. London, E. D.; Yamamura, H. I.; Bird, E. D.; & Coyle, J. T. (1981). Decreased receptor-binding sites for kainic acid in brains of patients with Huntington's disease. Biological Psychiatry, 16(2), 155-162.
43. Mangiarini, L.; Sathasivam, K.; Seller, M.; Cozens, B.; Harper, A.; Hetherington, C.; et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87(3), 493-506.
44. Martinez-Mir, M. I.; Probst, A.; & Palacios, J. M. (1991). Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease. Neuroscience, 42(3), 697-706.
45. Matsumoto, L.; Takuma, H.; Tamaoka, A.; Kurisaki, H.; Date, H.; Tsuji, S.; et al. (2010). CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS ONE, 5(11), e15522.
46. Mievis, S.; Blum, D.; & Ledent, C. (2011). A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiology of Disease, 41(2), 570-576.
47. Miller, C. A.; Gavin, C. F.; White, J. A.; Parrish, R. R.; Honasoge, A.; Yancey, C. R.; et al. (2010). Cortical DNA methylation maintains remote memory. Nature Neuroscience, 13(6), 664-666.
48. Miller, C. A.; & Sweatt, J. D. (2007). Covalent modification of DNA regulates memory formation. Neuron, 53(6), 857-869.
49. Mishina, M.; Ishiwata, K.; Naganawa, M.; Kimura, Y.; Kitamura, S.; Suzuki, M.; et al. (2011). Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. PLoS ONE, 6(2), e17338.
50. Münzel, M.; Globisch, D.; Brückl, T.; Wagner, M.; Welzmiller, V.; Michalakis, S.; et al. (2010). Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angewandte Chemie (International ed. in English), 49(31), 5375-5377.
51. Münzel, M.; Globisch, D.; & Carell, T. (2011). 5-Hydroxymethylcytosine, the sixth base of the genome. Angewandte Chemie (International ed. in English), 50(29), 6460-6468.
52. Nucifora, F. C, Jr, Sasaki, M.; Peters, M. F.; Huang, H.; Cooper, J. K.; Yamada, M.; et al. (2001). Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science, 291(5512), 2423-2428.
53. Orrú, M.; Zanoveli, J. M.; Quiroz, C.; Nguyen, H. P.; Guitart, X.; & Ferré, S. (2011). Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease. Experimental Neurology, 232(1), 76-80.
54. Penney, J. B, Jr, & Young, A. B. (1982). Quantitative autoradiography of neurotransmitter receptors in Huntington disease. Neurology, 32(12), 1391-1395.
55. Pieper, H. C.; Evert, B. O.; Kaut, O.; Riederer, P. F.; Waha, A.; & Wüllner, U. (2008). Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability. Neurobiology of Disease, 32(3), 521-527.
56. Pietrzak, M.; Rempala, G.; Nelson, P. T.; Zheng, J. J.; & Hetman, M. (2011). Epigenetic silencing of nucleolar rRNA genes in Alzheimer's disease. PLoS ONE, 6(7), e22585.
57. Popoli, P.; Blum, D.; Domenici, M. R.; Burnouf, S.; & Chern, Y. (2008). A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Current Pharmaceutical Design, 14(15), 1500-1511.
58. Popoli, P.; Pintor, A.; Domenici, M. R.; Frank, C.; Tebano, M. T.; Pèzzola, A.; et al. (2002). Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. The Journal of Neuroscience, 22(5), 1967-1975.
59. Reiner, A.; Albin, R. L.; Anderson, K. D.; D'Amato, C. J.; Penney, J. B.; & Young, A. B. (1988). Differential loss of striatal projection neurons in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America, 85(15), 5733-5737.
60. Richfield, E. K.; O'Brien, C. F.; Eskin, T.; & Shoulson, I. (1991). Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neuroscience Letters, 132(1), 121-126.
61. Saavedra, A.; Garcia-Martinez, J. M.; Xifro, X.; Giralt, A.; Torres-Peraza, J. F.; Canals, J. M.; et al. (2010). PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3 K/Akt pro-survival pathway in Huntington's disease striatum. Cell Death and Differentiation, 17(2), 324-335.
62. Schiffmann, S. N.; Fisone, G.; Moresco, R.; Cunha, R. A.; & Ferré, S. (2007). Adenosine A2A receptors and basal ganglia physiology. Progress in Neurobiology, 83(5), 277-292.
63. Song, C. X.; Szulwach, K. E.; Fu, Y.; Dai, Q.; Yi, C.; Li, X.; et al. (2011). Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nature Biotechnology, 29(1), 68-72.
64. Steffan, J. S.; Kazantsev, A.; Spasic-Boskovic, O.; Greenwald, M.; Zhu, Y. Z.; Gohler, H.; et al. (2000). The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proceeding of the National Academy of Sciences of the United States of America, 97(12), 6763-6768.
65. Sunahori, K.; Juang, Y. T.; & Tsokos, G. C. (2009). Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. Journal of Immunology, 182(3), 1500-1508.
66. Suzuki, M. M.; & Bird, A. (2008). DNA methylation landscapes: Provocative insights from epigenomics. Nature Review Genetics, 9(6), 465-476.
67. Szulwach, K. E.; Li, X.; Li, Y.; Song, C. X.; Wu, H.; Dai, Q.; et al. (2011). 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nature Neuroscience, 14(12), 1607-1616.
68. Taherzadeh-Fard, E.; Saft, C.; Wieczorek, S.; Epplen, J. T.; & Arning, L. (2010). Age at onset in Huntington's disease: Replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics, 11(4), 435-439.
69. Tahiliani, M.; Koh, K. P.; Shen, Y.; Pastor, W. A.; Bandukwala, H.; Brudno, Y.; et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, 324(5929), 930-935.
70. Tebano, M. T.; Martire, A.; Chiodi, V.; Ferrante, A.; & Popoli, P. (2010). Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: A possible key mechanism in the pathophysiology of Huntington's disease. ScientificWorldJournal, 10, 1768-1782.
71. The Huntington's Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72(6), 971-983.
72. Valinluck, V.; & Sowers, L. C. (2007). Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Research, 67(12), 946-950.
73. Valinluck, V.; Tsai, H. H.; Rogstad, D. K.; Burdzy, A.; Bird, A.; & Sowers, L. C. (2004). Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Research, 32(14), 4100-4108.
74. Van Ness, P. C.; Watkins, A. E.; Bergman, M. O.; Tourtellotte, W. W.; & Olsen, R. W. (1982). Gamma-Aminobutyric acid receptors in normal human brain and Huntington disease. Neurology, 32(1), 63-68.
75. Varani, K.; Bachoud-Lévi, A. C.; Mariotti, C.; Tarditi, A.; Abbracchio, M. P.; Gasperi, V.; et al. (2007). Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington's disease stages. Neurobiology of Disease, 27(1), 36-43.
76. Varani, K.; Vincenzi, F.; Tosi, A.; Gessi, S.; Casetta, I.; Granieri, G.; et al. (2010). A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J, 24(2), 587-598.
77. Vonsattel, J. P. (2008). Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathologica, 115(1), 55-69.
78. Vonsattel, J. P.; Myers, R. H.; Stevens, T. J.; Ferrante, R. J.; Bird, E. D.; & Richardson, E. P, Jr. (1985). Neuropathological classification of Huntington's disease. Journal of Neuropathology and Experimental Neurology, 44(6), 559-577.
79. Weber, M.; Hellmann, I.; Stadler, M. B.; Ramos, L.; Pääbo, S.; Rebhan, M.; et al. (2007). Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nature Genetics, 39(4), 457-466.
80. Whitehouse, P. J.; Trifiletti, R. R.; Jones, B. E.; Folstein, S.; Price, D. L.; Snyder, S. H.; et al. (1985). Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Annals of Neurology, 18(2), 202-210.
81. Xin, Y.; O'Donnell, A. H.; Ge, Y.; Chanrion, B.; Milekic, M.; Rosoklija, G.; et al. (2011). Role of CpG context and content in evolutionary signatures of brain DNA methylation. Epigenetics, 6(11), 1308-1318.
82. Yossifoff, M.; Kisliouk, T.; & Meiri, N. (2008). Dynamic changes in DNA methylation during thermal control establishment affect CREB binding to the brain-derived neurotrophic factor promoter. The European Journal of Neuroscience, 28(11), 2267-2277.
83. Young, A. B.; Greenamyre, J. T.; Hollingsworth, Z.; Albin, R.; D'Amato, C.; Shoulson, I.; et al. (1988). NMDA receptor losses in putamen from patients with Huntington's disease. Science, 241(4868), 981-983.
84. Yu, L.; Frith, M. C.; Suzuki, Y.; Peterfreund, R. A.; Gearan, T.; Sugano, S.; et al. (2004). Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses. Brain Research, 2004(1-2), 156-173.
85. Yu, Z. X.; Li, S. H.; Nguyen, H. P.; & Li, X. J. (2002). Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Human Molecular Genetics, 11(8), 905-914.
86. Zuccato, C.; Marullo, M.; Conforti, P.; MacDonald, M. E.; Tartari, M.; & Cattaneo, E. (2008). Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathology, 18(2), 225-238.